Health Care · Pharmaceutical Preparations

JBIO Jade Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 179874964 filings
Russell 2000

JBIO at a glance

Jade Biosciences, Inc. (JBIO, SEC CIK 1798749) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and Form 4 insider filings as recently as June 26, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Jade Biosciences, Inc. (JBIO) shares worth $282.4 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
26 funds
$282.4M · −1 vs prior quarter
Latest 8-K
Nov 13, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Net loss $35.1M vs $25.2M YoY, operating margin not applicable due to no revenue
  • JADE101 R&D $12.1M vs $6.0M, strongest program; JADE201 $3.5M vs $6.7M, weakest
  • Cash and investments $475.7M, operating cash use $96.6M for nine months
  • June offering net proceeds $161.6M, management expects funding for at least twelve months

AI summary of the JBIO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026
  • Results details are contained in Exhibit 99.1, the furnished earnings release

Item EX-99.1: Item EX-99.1

  • Q3 net loss $35.1M, up from $25.2M, reflecting accelerating investment in clinical development
  • Cash, cash equivalents and investments $475.7M, supporting operations and capital needs into Q4 2028
Filed Sep 30, 2026Full analysis →

Item 8.01: Other Events

  • JADE301 showed selective IFN-ß neutralization, with 11.3 pM binding affinity and 13 pM pSTAT inhibition
  • Dermal fibroblast MX-1 inhibition reached 11 pM, approximately 8-fold more potent than dazukibart
Filed Aug 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Jade Biosciences’ financial results for quarter ended June 30, 2026
  • Exhibit 99.1 contains the detailed results, providing the primary investor reference for the period

Item EX-99.1: Item EX-99.1

  • Positive interim JADE101 data: approximately 70% mean IgA reduction after one 700 mg dose, supporting potential every-12-week maintenance dosing
  • JADE101 Phase 2 underway with interim data expected in 2027; Phase 3 planned for first half of 2027 pending FDA feedback

AI summaries of JBIO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for JBIO

Don't miss the next JBIO filing

  • Alerts as it files. A push when JBIO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut JBIO, by share count.
  • Ask anything. An AI agent that reads every JBIO filing and answers with sources.

JBIO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Eisner MarkAJun 25, 2026-
Fairmount Funds Management LLCAJun 9, 2026-
Lavelle ErinAJun 9, 2026-
Klein Lawrence OttoAJun 9, 2026-
CAIN CHRISTOPHER W.AJun 9, 2026-
DOBMEIER ERICAJun 9, 2026-
Dahms Bradford D.AFeb 12, 2026-
King Andrew JamesAFeb 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$81.4M-$74.6M-$113.5M
Net Income-$75.5M-$69.6M-$127.4M
Balance Sheet
Total Assets$127.4M$80.3M$349.8M
Equity$109.5M$76.4M$332.5M
ROE-69.0%-91.1%-38.3%
Per Share
EPS$-2.87$-2.44$-3.19
Cash Flow
Operating CF-$56.8M-$71.2M-$94.7M
CapEx$142K-$196K

Source: XBRL data in Jade Biosciences, Inc. (JBIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate JBIO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
JBIO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$282.4M
Q2 202627$558.5M
Q1 202621$185.1M
Q4 202520$212.1M
Q3 202516$85.8M
Q2 202513$91.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 123 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

JBIO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 13, 2026Analysis
8-KNov 13, 2026Analysis-
8-KSep 30, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
SC 13GJul 17, 2026-
8-KJul 1, 2026Analysis-
4Jun 26, 2026--
8-KJun 26, 2026Analysis-
4Jun 11, 2026--
8-KJun 11, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 4, 2026Analysis
8-KJun 1, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KApr 22, 2026Analysis-
8-KApr 2, 2026Analysis-
10-KMar 6, 2026-
8-KMar 6, 2026Analysis-
SC 13GFeb 17, 2026-
SC 13GFeb 17, 2026-

Related Health Care companies

All Health Care →

JBIO SEC filings: frequently asked questions

Which institutions hold JBIO stock?

As of September 30, 2026, the largest Jade Biosciences, Inc. (JBIO) holders among the 13F filers tracked by SignalX were Franklin Resources ($57.3 million), BlackRock ($47.3 million), State Street Corp ($36.6 million), Vanguard Capital Management LLC ($33.0 million), JPMorgan Chase & Co ($20.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did JBIO report in its latest 8-K?

Jade Biosciences, Inc. (JBIO) filed an 8-K on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Jade Biosciences’ financial results for the quarter ended September 30, 2026.

What are the latest JBIO SEC filings?

Jade Biosciences, Inc. (JBIO) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 13, 2026, an 8-K current report on November 13, 2026 and a Form 4 insider filing on June 26, 2026.

What is JBIO's SEC CIK number?

Jade Biosciences, Inc. (JBIO)'s SEC Central Index Key (CIK) is 1798749. EDGAR lists every JBIO filing under that number.

Ask anything about JBIO

The research agent reads JBIO's filings, financials, insider trades and 13F holders, then answers with sources.